Autres langues MediciNova, Inc.

Actions

MNOV

US58468P2065

Temps Différé Nasdaq Autres places de cotation 16:49:12 20/06/2024			Varia. 5j.	Varia. 1 janv.
1,293 ^USD	-1,29%		-5,61%	-13,79%

05/06	MediciNova reçoit un avis d'autorisation pour un nouveau brevet couvrant le MN-166 (ibudilast) pour la prévention des métastases de divers cancers solides	CI
03/06	MediciNova, Inc. annonce les résultats de l'essai clinique de phase 1B/2A du Mn-166 (Ibudilast) chez des patients atteints de glioblastome lors de la réunion annuelle de l'American Society of Clinical Oncology (Asco) 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations	12:00
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 for the Prevention of Metastasis of Various Solid Cancer	06/06
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer	05/06
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer	05/06
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 for the Prevention of Metastasis of Various Solid Cancer	05/06
MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024	03/06
MediciNova, Inc. Announces Data from Phase 1B/2A Clinical Trial of Mn-166 in Glioblastoma Patients At the American Society of Clinical Oncology Annual Meeting 2024	03/06
MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 for Cardiometabolic Conditions	29/05
MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions	28/05
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer	20/05
MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 for the Prevention of Metastasis of Eye Cancer	20/05
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome	14/05
MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome	14/05
MediciNova: Q1 Earnings Snapshot	10/05
MediciNova, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)	07/05
MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)	07/05
MediciNova, Inc. Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166	07/05
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting	03/04
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)	03/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues MediciNova, Inc.

Actions

MNOV

US58468P2065

Autres langues

Filtres